Thermo Fisher Scientific Nivolumab Monoclonal Antibody (8G6G3D8)

Thermo Fisher Scientific Nivolumab Monoclonal Antibody (8G6G3D8)

Applications

• ELISA

Tested Dilution: 0.01–0.1 µg/mL

Product Specifications

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.

Nivolumab (Opdivo) is a humanized monoclonal antibody approved by the U.S. FDA for the treatment of unresectable or metastatic melanoma.
Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in activation of T-cell-mediated immune responses against tumor cells.

GenScript Anti-Nivolumab Antibody (8G6G3D8), mAb, Mouse is produced from a hybridoma formed by fusion of partner and B-lymphocytes obtained from a mouse immunized with Nivolumab.

Target Information

Nivolumab (Opdivo) is a humanized monoclonal antibody that binds to PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, leading to activation of T-cell-mediated immune responses against tumor cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.